Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab

Vista sencilla de ítem
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorWills, Beatriz
dc.contributor.authorArrieta, Oscar
dc.contributor.authorReguart, Noemi
dc.contributor.authorCorrales, Luis
dc.contributor.authorOtero, Jorge
dc.contributor.authorCuello, Mauricio
dc.contributor.authorRolfo, Christian
dc.contributor.authorRosell, Rafael
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorRuiz-Patiño, Alejandro
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorMartín, Claudio
dc.contributor.authorPino, Luis Eduardo
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.date.accessioned2020-05-14T19:39:19Z
dc.date.available2020-05-14T19:39:19Z
dc.date.issued2017
dc.description.abstractenglishBackground: Heavily treated patients with nonsmall cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated. Progression-free (PFS) and overall (OS) survival were monitored. Results: Median follow-up was 13.2 months. Twenty-three patients had received three or more prior therapy lines. Overall response rate was 32% [95% confidence interval (CI)=22%-39%] and 26% of patients achieved stable disease. Median PFS was 4.4 (95% CI=2.8- 8.3) months and median OS 18.0 (95% CI=16.2-30.7) months. Nine patients harboring EGFR mutations had a longlasting partial response. A shorter OS was found in patients with a higher TIMP1 expression (p=0.006). Conclusion: Irinotecan combined with bevacizumab had favorable antitumor activity in heavily pretreated patients with NSCLC. These results suggest this is a reasonable strategy, particularly for patients with low TIMP1 expression.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.21873/anticanres.12097
dc.identifier.issn0250-7005
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2790
dc.language.isoeng
dc.publisherInternational Institute of Anticancer Researchspa
dc.publisher.journalAnticancer Researchspa
dc.relation.ispartofseriesAnticancer Research, 0250-7005, Vol. 37, Nro.11, 2017, p.6429-6436spa
dc.relation.urihttps://ar.iiarjournals.org/content/37/11/6429.short
dc.rights.creativecommons2017
dc.rights.localAcceso cerradospa
dc.subject.decsTratamiento farmacológicospa
dc.subject.decsCalidad de vidaspa
dc.subject.decsNeoplasias pulmonaresspa
dc.subject.keywordsIrinotecanspa
dc.subject.keywordsBevacizumabspa
dc.subject.keywordsTIMP1spa
dc.subject.keywordsEGFR mutationspa
dc.subject.keywordsGene expressionspa
dc.titleSurvival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumabspa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Wills B., Cardona A.F., Rojas L., Ruiz-Patiño A._2017.pdf
Tamaño:
224.28 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos